Nov. 13 at 2:13 PM
$ASND call nuggets:
-Less than 5% of US patients are currently on Yorvipath
-See significant growth with around 80,000 to 90,000 patients already diagnosed with chronic hypopara and 3,000 to 4,000 new patients diagnosed each year
-Confident they can achieve EUR 5 billion or more in annual product revenue in 2030
-For TransCon once-monthly semaglutide, believe they have a unique profile because of the slow release from the product system to a level where the Tmax is very late (don't have a high slope). This is NOT one single program,
$NVO muscle= move forward via multiple ways
